Skip to content

Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation

Dietary Ketosis a Metabolic Sister to Calorie Restriction (CR): Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation Via the SAM/SAH Axis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03319173
Enrollment
98
Registered
2017-10-24
Start date
2017-10-15
Completion date
2018-09-30
Last updated
2019-11-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome, Mild Cognitive Impairment

Keywords

Mild Cognitive Impairment, AMPK activation, DNA global hypo-methylation, Metabolic Syndrome, Ketogenic diet, SAM/SAH Index, S-adenosylmethionine (SAM), S-adenosylhomocysteine (SAH), Region-Specific hyper-methylation, mTOR kinase pathway, AMP/ATP ratio, Low Reduction Potential, High Reduction Potential, Delta G, Exergonic, Endergonic, Epigenetic Histone Modification, Montreal Cognitive Assessment (MoCA), Brief Visual Memory Test-Revised (BVMT-R), Rey Auditory Verbal Learning Task (RAVLT), HOMA-IR

Brief summary

The study explores whether selective memory complaints (SMC), mild cognitive impairment (MCI) and the comorbidity of Metabolic Syndrome symptomatic of peripheral and cerebral hypo-metabolism with corresponding epigenetic shifts in global DNA (deoxyribonucleic acid) methylation (away from nutrient availability and toward biosynthesis) are initiated by chronic metabolic inflexibility, over-activation of the mTOR (mammalian target of rapamycin) pathway, and the deregulation of neural oxidative phosphorylation.

Detailed description

Nutritional epigenetics denotes gene-diet interactions and highlights the modulatory role of cellular energy status in aging and age-related diseases like cancer, cardiovascular disease (CVD), diabetes and neurodegeneration. Nutrients are epigenetic modifiers; macro and micronutrients regulate the placement and distribution of DNA histone modifiers distinguishing phenotype from genotype. Cellular energy status (AMP/ATP) modulates the regulatory mechanics of DNA methylation via the SAM (S-adenosylmethionine) methlytransferase and the SAH (S-adenosyl homocysteine) methyltransferase inhibitor index. Whole blood histamine and homocysteine levels provide additional information on the status of methylation. Hyperinsulinemia and cellular insulin resistance dysregulate nutrient sensing pathways; perpetual fed-state signaling exacerbates systemic metabolic inflexibility. Chronic elevations in insulin with long-standing impairments in glucose delivery are associated with profound changes in epigenetic expression consequent of hyper-activation of mTOR and inhibition of AMPK kinase pathways. Dietary ketosis is known to govern adaptive mitonuclear energy availability by increasing cellular reduction potential via \>AMP/ATP ratio. AMPK activation adapts rRNA synthesis away from fed-state growth/storage toward energy production/release, common to fasted-states. Research suggests that induced and controlled dietary ketogenesis, a fasting mimetic, transcriptionally modifies gene expression thereby attenuating metabolic diseases. The study will explore whether early stage memory loss (SMC & MCI) and comorbidity of Metabolic Syndrome are symptomatic of peripheral and cerebral hypo-metabolism resultant of sustained cellular insulin resistance. The investigators will attempt to show that consequent to systemic hyperinsulinemia, mitonuclear crosstalk dysregulates the energy sensing kinases, mTOR/AMPK, thereby modifying the intra/extracellular nutrient signaling pathways. The suppression of AMPK, coupled with chronic fed-state signaling, adapts rRNA synthesis away from nutrient availability toward ATP consuming processes. Increased biosynthesis of proteins, lipids and cholesterol with concurrent inhibition of fat oxidation, energy cofactors (NAD+, SAHH) and programmed apoptosis results in the epigenetic drift of methylation toward global gene activation with region-specific silencing of key regulatory/longevity genes, SIRTs (sirtuins), FOX03 and Nrf2. This global shift in energy is marked by suppression of the SAM/SAH methylation index and correlative jumps in whole blood histamine and/or homocysteine. The study explores whether the aforementioned shift in nutrient sensing pathways modulates metabolic inflexibility via energy shunts toward cytosolic, substrate level phosphorylation via activation of PDK (pyruvate dehydrogenase kinase). An insulin resistant energy surplus (\<AMP/ATP) fosters low cellular reduction potential, which triggers mitonuclear crosstalk inhibiting oxidative ATP via PDC (pyruvate dehydrogenase complex), the regulatory gateway between anaerobic glycolysis and oxidative mitochondrial respiration. The study will attempt to show that induced and controlled dietary ketosis initiates the spontaneous/favorable release of energy ( \>AMP/ATP), activating the AMPK circuitry thereby inhibiting the synthesis/storage of protein, cholesterol and lipids. Thus, a shift in cellular energy from low reduction potential (ATP/NADH) to high reduction potential (AMP/NAD+) attenuates methylation drift evidenced by marked reductions in biosynthesis: fasting lipid profile (TRI., VLDL, LDL, HDL), LP-IR score (particle concentration/size), HgA1c, fasting insulin, HOMA-IR and epigenetic modification of DNA measured by improved methylation index (\>SAM/SAH) with correlating reductions in whole blood histamine and/or homocysteine. The resultant change in cerebral glucose metabolism and correlative improvement in SMC/MCI will be assessed by valid clinical measures of cognition: Montreal Cognitive Assessment (MoCA), Brief Visual Memory Test-Revised (BVMT-R) and Rey Auditory Verbal Learning Task (RAVLT) administered at baseline and weeks 2/4/6/8/10/12. Research Question: Are selective memory complaints (SMC), mild cognitive impairments (MCI) and comorbid Metabolic Syndrome symptomatic of peripheral/cerebral insulin resistance with a resultant epigenetic drift in methylation away from energy production toward anabolic synthesis/storage, initiated and sustained by metabolic inflexibility, aerobic glycolysis and PDK inhibition of oxidative phosphorylation?

Interventions

BEHAVIORALDietary intervention

Subjects in the experimental group will receive clinically regulated meal plans designed to facilitate prolonged benign dietary ketosis (BDK) in order to regulate glucose with restored insulin sensitivity focused at reversing the impaired capacity to switch between fat and carbohydrate oxidation. Subjects in the control group will follow the their current dietary protocol (Standard American Diet-SAD).

Sponsors

University of Minnesota
CollaboratorOTHER
Bristlecone Health, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

To assess differences between the control and experimental groups, a mixed model will be fit for each variable separately using both baseline (week 0) and post program (week 12) values for each subject. Models will include week, group, and their interaction as fixed effects, gender as a covariate, and subject as a random effect. To assess significant differences, we will use the difference at week 12 adjusted for the baseline difference, and will report p-values, least squares means, and 95% confidence intervals. Further analysis of treatment effects over time will be examined by comparing the within-group differences over time.

Eligibility

Sex/Gender
ALL
Age
35 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Male or Female (age 35-80) * Previously diagnosed with MetS and/or T2DM as measured by possessing at least two of the following physiological measures: type 2 diabetes, BMI \> 30, HgA1c \> 5.7%, waist/height ratio \> .6, fasting glucose \> 125 mg/dL * Subjective Memory Complaints (SCM) - Subjects score \> 3 'yes' answers on the Subjective Memory Complaints Questionnaire * Previously diagnosed with Mild Cognitive Impairment (MCI)

Exclusion criteria

* Previously diagnosed with Alzheimer's disease (AD), dementia or Parkinson's disease

Design outcomes

Primary

MeasureTime frameDescription
MoCA (Montreal Cognitive Assessment)12 weeksMeasures changes in cognitive function over time. Score: 30 points (maximum), 0 points (minimum). Score \>25 = normal cognitive function. Score 17-25 = mild cognitive impairment (MCI). Score \<17 = increased likelihood of Alzheimer's Disease or dementia.

Secondary

MeasureTime frameDescription
NMR Lipoprofile Particle Size - LP-IR Score (Lipoprotein Insulin Resistance) Ideal Range: <4512 weeksLipoprotein insulin resistance (LP-IR) is an aggregate score of the 6 lipoprotein parameters range from 0 to 100, with higher scores indicating greater insulin resistance (IR).
Fasting Triglycerides12 weeksAssessment of changes in fasting triglycerides over time. Ranges: \< 150 mg/dL
Triglyceride/HDL Ratio12 weeksAssessment of changes in Triglyceride/HDL ratio over time.
Fasting Insulin12-weeksAssessment of changes in fasting insulin over time. Ranges: \< 2.6-11.1 mU/L
Fasting Glucose12-weeksAssessment of changes in fasting glucose over time. Ranges: \< 74-100 mg/dL
HOMA-IR12-weeksAssessment of changes in HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) over time. Ranges: \< 1.0
HgA1c12-weeksAssessment of changes in HgA1c (Hemoglobin A1c) over time.
NMR Lipoprofile Particle Size - Small LDL-P12 weeksAssessment of changes in Small LDL-P (total small Pattern B)
Body Fat Mass (BFM)12-weeksAssessment of changes in body fat mass over time as measured in pounds.
VLDL12-weeksAssessment of changes in VLDL (very low density lipoprotein carrier) over time. Ranges: \< 5-40 mg/dL
SAM/SAH Ratio (S-adenosylmethionine/S-adenosylhomocysteine)12-weeksAssessment of changes in SAM/SAH (S-adenosylmethionine/S-adenosylhomocysteine) ratio Range: \>4.0
SAM (S-adenosylmethionine)12-weeksAssessment of changes in SAM (S-adenosylmethionine)
SAH (S-adenosylhomocysteine)12-weeksAssessment of changes in SAH (S-adenosylhomocysteine) Range: 10-22 nmol/L
Adenosine12-weeksAssessment of changes in Adenosine Range: 20-80 nmol/L
Weight12-weeksAssessment of changes in weight over time as measured in pounds.

Countries

United States

Participant flow

Participants by arm

ArmCount
Experimental Group
Dietary interventions for subjects in the experimental group include clinically regulated meal plans designed to facilitate prolonged benign dietary ketosis (BDK) in order to regulate glucose with restored insulin sensitivity focused at reversing the impaired capacity to switch between fat and carbohydrate oxidation. Subjects will consume 3 meals per day with the following approximate macronutrient breakdown per meal: 65% fat, 25% protein, 10% carbohydrate. Both groups will play the Advanced PEAK brain training games on iPhone, iPad or Android devices for 75 minutes per week. Dietary intervention: Subjects in the experimental group will receive clinically regulated meal plans designed to facilitate prolonged benign dietary ketosis (BDK) in order to regulate glucose with restored insulin sensitivity focused at reversing the impaired capacity to switch between fat and carbohydrate oxidation.
48
Control Group
Dietary interventions for subjects in the control group include the subjects' current dietary protocol (Standard American Diet-SAD). Subjects will consume 4-6 small meals per day with the following approximate macronutrient breakdown per meal: 50% carbohydrate, 35% protein, 15% fat. Both groups will play the Advanced PEAK brain training games on iPhone, iPad or Android devices for 75 minutes per week. Dietary intervention: Subjects in the control group will follow the their current dietary protocol (Standard American Diet-SAD).
50
Total98

Baseline characteristics

CharacteristicExperimental GroupControl GroupTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
7 Participants6 Participants13 Participants
Age, Categorical
Between 18 and 65 years
41 Participants44 Participants85 Participants
MoCA (Montreal Cognitive Assessment)28.38 units on a scale20.22 units on a scale24.30 units on a scale
Race and Ethnicity Not Collected0 Participants
Region of Enrollment
United States
48 Participants50 Participants98 Participants
Sex: Female, Male
Female
25 Participants25 Participants50 Participants
Sex: Female, Male
Male
23 Participants25 Participants48 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 480 / 50
other
Total, other adverse events
0 / 480 / 50
serious
Total, serious adverse events
0 / 480 / 50

Outcome results

Primary

MoCA (Montreal Cognitive Assessment)

Measures changes in cognitive function over time. Score: 30 points (maximum), 0 points (minimum). Score \>25 = normal cognitive function. Score 17-25 = mild cognitive impairment (MCI). Score \<17 = increased likelihood of Alzheimer's Disease or dementia.

Time frame: 12 weeks

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
Experimental GroupMoCA (Montreal Cognitive Assessment)28.38 score on a scaleStandard Error 0.22
Control GroupMoCA (Montreal Cognitive Assessment)20.22 score on a scaleStandard Error 0.22
p-value: <0.000195% CI: [7.79, 8.7]Regression, Linear
Secondary

Adenosine

Assessment of changes in Adenosine Range: 20-80 nmol/L

Time frame: 12-weeks

ArmMeasureValue (GEOMETRIC_LEAST_SQUARES_MEAN)
Experimental GroupAdenosine23.363 nmol/L
Control GroupAdenosine21.475 nmol/L
p-value: <0.000195% CI: [1.096, 1.149]Regression, Linear
Secondary

Body Fat Mass (BFM)

Assessment of changes in body fat mass over time as measured in pounds.

Time frame: 12-weeks

ArmMeasureValue (GEOMETRIC_LEAST_SQUARES_MEAN)
Experimental GroupBody Fat Mass (BFM)67.95 pounds
Control GroupBody Fat Mass (BFM)79.35 pounds
p-value: <0.000195% CI: [0.71, 0.8]Regression, Linear
Secondary

Fasting Glucose

Assessment of changes in fasting glucose over time. Ranges: \< 74-100 mg/dL

Time frame: 12-weeks

ArmMeasureValue (GEOMETRIC_LEAST_SQUARES_MEAN)
Experimental GroupFasting Glucose85.9 mg/dL
Control GroupFasting Glucose109.61 mg/dL
p-value: <0.000195% CI: [0.72, 0.78]Regression, Linear
Secondary

Fasting Insulin

Assessment of changes in fasting insulin over time. Ranges: \< 2.6-11.1 mU/L

Time frame: 12-weeks

ArmMeasureValue (GEOMETRIC_LEAST_SQUARES_MEAN)
Experimental GroupFasting Insulin7.32 mU/L
Control GroupFasting Insulin11.25 mU/L
p-value: <0.000195% CI: [0.4, 0.49]Estimate
Secondary

Fasting Triglycerides

Assessment of changes in fasting triglycerides over time. Ranges: \< 150 mg/dL

Time frame: 12 weeks

ArmMeasureValue (GEOMETRIC_LEAST_SQUARES_MEAN)
Experimental GroupFasting Triglycerides87.23 mg/dL
Control GroupFasting Triglycerides131.73 mg/dL
p-value: <0.000195% CI: [0.47, 0.56]Regression, Linear
Secondary

HgA1c

Assessment of changes in HgA1c (Hemoglobin A1c) over time.

Time frame: 12-weeks

ArmMeasureValue (GEOMETRIC_LEAST_SQUARES_MEAN)
Experimental GroupHgA1c5.19 percentage of glycated hemoglobin
Control GroupHgA1c5.82 percentage of glycated hemoglobin
p-value: <0.000195% CI: [0.85, 0.88]Regression, Linear
Secondary

HOMA-IR

Assessment of changes in HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) over time. Ranges: \< 1.0

Time frame: 12-weeks

ArmMeasureValue (GEOMETRIC_LEAST_SQUARES_MEAN)
Experimental GroupHOMA-IR1.55 units on a scale
Control GroupHOMA-IR3.05 units on a scale
p-value: <0.000195% CI: [0.3, 0.37]Estimate
Secondary

NMR Lipoprofile Particle Size - LP-IR Score (Lipoprotein Insulin Resistance) Ideal Range: <45

Lipoprotein insulin resistance (LP-IR) is an aggregate score of the 6 lipoprotein parameters range from 0 to 100, with higher scores indicating greater insulin resistance (IR).

Time frame: 12 weeks

ArmMeasureValue (GEOMETRIC_LEAST_SQUARES_MEAN)
Experimental GroupNMR Lipoprofile Particle Size - LP-IR Score (Lipoprotein Insulin Resistance) Ideal Range: <4532.13 score on a scale
Control GroupNMR Lipoprofile Particle Size - LP-IR Score (Lipoprotein Insulin Resistance) Ideal Range: <4550.66 score on a scale
p-value: <0.000195% CI: [0.41, 0.52]Regression, Linear
Secondary

NMR Lipoprofile Particle Size - Small LDL-P

Assessment of changes in Small LDL-P (total small Pattern B)

Time frame: 12 weeks

ArmMeasureValue (GEOMETRIC_LEAST_SQUARES_MEAN)Dispersion
Experimental GroupNMR Lipoprofile Particle Size - Small LDL-P276.24 nmol/LStandard Error 29.25
Control GroupNMR Lipoprofile Particle Size - Small LDL-P588.08 nmol/LStandard Error 61.02
p-value: <0.000195% CI: [0.31, 0.39]Regression, Linear
Secondary

SAH (S-adenosylhomocysteine)

Assessment of changes in SAH (S-adenosylhomocysteine) Range: 10-22 nmol/L

Time frame: 12-weeks

ArmMeasureValue (GEOMETRIC_LEAST_SQUARES_MEAN)
Experimental GroupSAH (S-adenosylhomocysteine)18.257 nmol/L
Control GroupSAH (S-adenosylhomocysteine)19.566 nmol/L
p-value: <0.000195% CI: [0.91, 0.94]Regression, Linear
Secondary

SAM (S-adenosylmethionine)

Assessment of changes in SAM (S-adenosylmethionine)

Time frame: 12-weeks

ArmMeasureValue (GEOMETRIC_LEAST_SQUARES_MEAN)
Experimental GroupSAM (S-adenosylmethionine)89.784 nmol/L
Control GroupSAM (S-adenosylmethionine)88.177 nmol/L
p-value: <0.000195% CI: [1.025, 1.049]Regression, Linear
Secondary

SAM/SAH Ratio (S-adenosylmethionine/S-adenosylhomocysteine)

Assessment of changes in SAM/SAH (S-adenosylmethionine/S-adenosylhomocysteine) ratio Range: \>4.0

Time frame: 12-weeks

ArmMeasureValue (GEOMETRIC_LEAST_SQUARES_MEAN)
Experimental GroupSAM/SAH Ratio (S-adenosylmethionine/S-adenosylhomocysteine)4.938 ratio
Control GroupSAM/SAH Ratio (S-adenosylmethionine/S-adenosylhomocysteine)4.491 ratio
p-value: <0.000195% CI: [1.104, 1.156]Regression, Linear
Secondary

Triglyceride/HDL Ratio

Assessment of changes in Triglyceride/HDL ratio over time.

Time frame: 12 weeks

ArmMeasureValue (GEOMETRIC_LEAST_SQUARES_MEAN)
Experimental GroupTriglyceride/HDL Ratio1.67 ratio
Control GroupTriglyceride/HDL Ratio2.69 ratio
p-value: <0.000195% CI: [0.4, 0.49]Regression, Linear
Secondary

VLDL

Assessment of changes in VLDL (very low density lipoprotein carrier) over time. Ranges: \< 5-40 mg/dL

Time frame: 12-weeks

ArmMeasureValue (GEOMETRIC_LEAST_SQUARES_MEAN)
Experimental GroupVLDL17.45 mg/dL
Control GroupVLDL26.35 mg/dL
p-value: <0.000195% CI: [0.47, 0.56]Regression, Linear
Secondary

Weight

Assessment of changes in weight over time as measured in pounds.

Time frame: 12-weeks

ArmMeasureValue (GEOMETRIC_LEAST_SQUARES_MEAN)
Experimental GroupWeight200.23 pounds
Control GroupWeight210.60 pounds
p-value: <0.000195% CI: [0.85, 0.88]Regression, Linear

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026